ICU MedicalICUI
About: ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Employees: 15,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
85% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $5.79M
5% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 95
5% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 39
0.63% less ownership
Funds ownership: 99.15% [Q3] → 98.52% (-0.63%) [Q4]
1% less funds holding
Funds holding: 286 [Q3] → 283 (-3) [Q4]
15% less capital invested
Capital invested by funds: $4.41B [Q3] → $3.74B (-$665M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 0 (-4) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Keybanc Tim Rezvan 15% 1-year accuracy 7 / 46 met price target | 40%upside $191 | Overweight Maintained | 21 Apr 2025 |
Financial journalist opinion
Based on 4 articles about ICUI published over the past 30 days









